For this reason, supplementary biomarkers to CEA, such as cancer antigen 19.9 (CA19.9) [6], cancer antigen 125 (CA125) [7], cancer antigen 72-4 (CA72-4) [8], and tumor-associated glycoprotein 72 (TAG 72) [9], have also been recognized and suggested as aids in CRC diagnosis, post-operative surveillance, as well as monitoring response to treatment [3,5]. The gene discussed is MUC16; the disease is colorectal carcinoma.